# Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

> **NCT06846710** · PHASE1 · RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 132 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** HS-20118
- **OTHER:** HS-20118 placebo

## Key facts

- **NCT ID:** NCT06846710
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-02
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846710, "Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06846710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*